Axxam is a privately-owned contract research and discovery company with a team of 90 highly skilled employees; most of them experienced scientists, located at OpenZone Science Park, Bresso (Milan, Italy). Since its inception in 2001, as a spin-out from the Bayer Group, AXXAM has built up an integrated discovery platform called ‘Lead Engine’, which consists of ‘assay development’, ‘high throughput screening’, ‘hit follow-up’ and ‘medicinal chemistry’ modules. This streamlined industrial platform is used for the discovery of novel bioactive compounds and is provided by AXXAM services’ unit. The company has developed a multi-year proven track record as a third-party research and discovery services’ provider for the life science industry.
AXXAM has been collaborating with more than 50 international partners, ranging from small Biotech to large pharmaceutical companies and agrochemical companies, and a growing network of research institutions. In the last few years, AXXAM has expanded its business model by establishing its own suite of internal discovery programs against attractive biomedical targets, which are then out-licensed at the lead candidate stage to a collaborative/licensing partner.
Bayer AG is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the group aims to create value through innovation, growth and high earning power. Bayer AG is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. Bayer AG Pharmaceuticals Lead Discovery and Drug Development have substantial experience in exploiting SLC transporters as drug targets. Despite being a druggable target class, there is a lack of broadly applicable methods to reveal physiological and molecular function of a majority of SLC transporters. Bayer AG regards RESOLUTE as a unique opportunity to address these shortcomings and contribute to the investigation of this underexplored target class.
Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Max-Planck Institute for Medical Research
The Max-Planck Institute for Medical Research (Heidelberg) focuses its research on the interface between biology, chemistry, physics and materials science. A specific goal is to discover and develop novel chemical and physical approaches that analyze biomolecular mechanisms, modulate and control cellular physiological function, and image molecular interactions at the nanometer level, non-invasively and in real-time. These approaches should provide a quantitative understanding of the (patho)physiology of cells at the molecular level.
The Novartis mission is to discover new ways to improve and extend peoples's live. We use science based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Research and development is the core of the Novartis strategy and a foundation of our future.
NIBR: The innovation engine
The Novartis Institute for biomedical research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries, and use powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients. We re-imagine medicine. Switzerland is a key location for Novartis research. The Basel site is one of NIBR's key research locations globally and is home of more than 2.200 scientists, physicians and business professionals. These researchers use pioneering methods and cutting-edge technology to achieve breakthroughs in areas such as the treatment of musculoskeletal disorders, oncology, transplantation, and autoimmune diseases. With its global organization, NIBR maintains more than 300 partnerships with universities and private research institutions throughout the world.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
The Medicine Design group within Pfizer will contribute to the Unlock SLC/RESOLUTE project with contributors located in the United States. The contributors have backgrounds in medicinal chemistry, pharmacology, metabolomics, bioinformatics, data analysis and laboratory based SLC research.
Research Center for Molecular Medicine - CeMM
The mission of the Research Center for Molecular Medicine of the Austrian Academy of Sciences (Vienna), founded 10 years ago, is to strengthen biomedical research in Austria and to achieve maximum scientific innovation in molecular medicine to improve healthcare. Strategically located in a new purpose-built research building in the heart of the General Hospital in Vienna (the largest single-site hospital in Europe with 2,000 MDs), a team of 130 scientists and medical doctors from 37 nations pursues free-minded life science research in a large and vibrant hospital environment. Its research is based on post-genomic technologies and focuses on immune disorders, infections, cancer and metabolic disorders. Composed of 12 independent research groups, CeMM operates in a unique mode of super-cooperation, connecting biology with medicine, experiments with computation, discovery with translation, and science with society and the arts. CeMM is one of the founding members of EU-Life, an alliance of 13 top European research centers established to exchange best practices in life sciences, and has also been voted Europe’s best place to work in academia in a 2012 survey by The Scientist. CeMM GmbH’s goal is to pioneer the science that nurtures the precise, personalized, and preventive medicine of the future.
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 100,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life. With a presence in more than 100 countries and industrial sites in more than 40 countries, our industrial network, know-how and teams deliver health solutions to millions of individuals with high quality and maximum safety, regardless wherever they are manufactured. We concentrate our research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide.
Structural Genomics Consortium
The Structural Genomics Consortium (SGC) is a not-for-profit public-private partnership to accelerate drug discovery through open access research by 250+ scientists, located at 6 sites across the globe. The SGC Oxford over the past 13 years has become a research centre leading in human protein structure and chemical biology, with the structure determination of over 500 novel human soluble proteins, 30 protein-protein complexes and 10 human integral membrane proteins (IMPs). It has strong and expanding capabilities in assay development and chemical screening, in particular in the context of its impactful chemical probe programme.
These successful developments and the SGC Oxford international contribution have been sustained through active and innovative method and technology development. The SGC is renowned for the quality and reproducibility of the generated data and reagents, as well as for the robust methodologies developed. It has been a training ground for many scientists worldwide.
SGC Oxford through its research, technological and methodological developments and reagents has naturally become over the years an epicenter for collaborations, both with academia and with industry. It has built as international collaborative network spanning 9 pharmaceutical partners, over 300 leading academic labs and several biotech companies.
The SGC is one of the major champions for open source science and drug discovery. The reagents and data produced by the SGC are delivered in an open manner framework to facilitate collaboration, reduce wastage, and catalyse academic and industrial science. The SGC has produced over 400 papers, co-authored with over 1,300 different authors from 35 academic institutions and 20 companies. Membrane protein structural biology is exclusively carried out at the largest site located in Oxford, managing a total of more than 20 scientists dedicated to the production of membrane proteins for structural studies by cryo-EM and X-ray crystallography.
The University of Manchester
The University of Manchester, represented by the Manchester Institute of Biotechnology (www.mib.ac.uk), came into being in 2004 through a merger of the Victoria University of Manchester (VUM) and the University of Manchester Institute of Science and Technology (UMIST). In the most recent UK research evaluation, known as the REF, 83% of the research activity was judged to be ‘world-leading’ or ‘internationally excellent’, and it was ranked in 5th place in terms of research power. The MIB is a physical building (opened in 2006) and multidisciplinary research centre that houses some 47 research groups (~500 investigators) devoted to multidisciplinary and applied science. It houses multiple Centres of Excellence, including the Manchester Centre for Integrative Systems Biology, (mcisb.org), the Centre of Excellence for Biocatalysis, Biotransformations and Biocatalytic Manufacture (www.coebio3.manchester.ac.uk), the Centre of Excellence in Biopharmaceuticals (www.coebp.ls.manchester.ac.uk), and the Centre for Synthetic Biology of Fine and Speciality Chemicals (SYNBIOCHEM) (synbiochem.co.uk). The portfolio of funded research grants at the MIB alone exceeds £100M.
University of Leiden
Leiden University is one of Europe’s leading research universities with 7 faculties in Leiden and The Hague. The University of Leiden has 6,500+ staff members and 26,900 students. The University of Leiden has been an international university from its founding in 1575. The motto of the University is ‘Praesidium Libertatis’ – Bastion of Freedom. In the first decades of its existence, the university was host to many international students, from Europe and beyond. Since those early days, it has developed into a truly international university, annually hosting more than 3,000 international and exchange students in its Bachelor and Master programs, almost 1,000 international PhD students and more than 800 international academic staff. Leiden University continuously ranks in the top 100 of universities worldwide in all relevant rankings. The university is member of several international university networks. Membership in the League of European Research Universities is of particular strategic importance for Leiden University.
The Leiden Academic Centre for Drug Research of the University of Leiden is a first-class environment for innovation in drug research as judged by an international peer review committee in 2016. Its research divisions encompass all disciplines relevant for advanced drug research, including pharmacology, toxicology, medicinal chemistry and analytical biosciences. The center is continuously positioned in the top-20 of the QS World University Rankings.
University of Oxford
The University of Oxford is a world-leading centre of learning, teaching and research and the oldest university in the English-speaking world. Oxford’s research activity involves 70+ departments, 1,600+ academic staff, 4,100+ research & research support staff, and 5,500+ graduate research students. The Medical Sciences Division is an internationally recognized centre of excellence for biomedical and clinical research.
University of Vienna
The University of Vienna encompasses a broad spectrum of scientific disciplines, ranging from theology, jurisprudence, economics, computer science, to the humanities and to the social and natural sciences (https://www.univie.ac.at). The Pharmacoinformatics Research Group (https://pharminfo.univie.ac.at), headed by G. Ecker, is part of the Division of Drug Design and Medicinal Chemistry at the Department of Pharmaceutical Chemistry, Faculty of Life Sciences. The groups’ expertise lies on structural modelling of proteins, structure-based drug design, chemometric and in silico chemogenomic methods, statistical modelling and machine learning approaches for development of predictive computational systems with focus on transporters. Furthermore, the group has ample experience in integration and mining of open data sources for answering complex drug-discovery related research questions. Especially the generation of data mining workflows as well as knowledge on transporter modeling will be of special use for RESOLUTE.
Vifor Pharma Group
Vifor Pharma Group is a global pharmaceutical company that researches, develops, produces and markets its own pharmaceutical products. The company aims to become the global leader in its three key therapeutic areas: iron deficiency, nephrology and cardio-renal; and is the partner of choice for innovative, patient-focused solutions. As a Vifor Pharma Group company, Vifor Pharma focuses its pre-clinical research on the development of novel medicines. One recent example, VIT-2763, the first-ever oral ferroportin inhibitor for preventing iron overload, entered clinical development in March 2018. Ferroportin (SLC40A1) belongs to the family of solute carrier transporters which are at the heart of the ReSOLUTE project. Vifor Pharma’s expertise in the analysis of inorganic ions and the development of transporter cellular assays will be deployed to support the ReSOLUTE initiative.